Raclopride

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Raclopride
Accession Number
DB12518
Description

Raclopride has been used in trials studying Parkinson Disease.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 347.24
Monoisotopic: 346.0850979
Chemical Formula
C15H20Cl2N2O3
Synonyms
  • Racloprida
  • Raclopride
  • Raclopridum
External IDs
  • FLA 870

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UDopamine D2 receptor
antagonist
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Raclopride.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Raclopride.
AclidiniumRaclopride may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Raclopride.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Raclopride.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Raclopride.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Raclopride.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Raclopride.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Raclopride.
AlverineThe risk or severity of adverse effects can be increased when Alverine is combined with Raclopride.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylamides
Alternative Parents
Methoxyphenols / 3-halobenzoic acids and derivatives / Benzamides / Benzoyl derivatives / Dichlorobenzenes / Anisoles / Methoxybenzenes / O-chlorophenols / P-chlorophenols / Phenoxy compounds
show 12 more
Substituents
1,3-dichlorobenzene / 2-chlorophenol / 2-halophenol / 3-halobenzoic acid or derivatives / 4-chlorophenol / 4-halophenol / Alkyl aryl ether / Amine / Amino acid or derivatives / Anisole
show 34 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
430K3SOZ7G
CAS number
84225-95-6
InChI Key
WAOQONBSWFLFPE-VIFPVBQESA-N
InChI
InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
IUPAC Name
3,5-dichloro-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-hydroxy-6-methoxybenzamide
SMILES
CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC

References

General References
Not Available
PubChem Compound
3033769
PubChem Substance
347828748
ChemSpider
2298373
BindingDB
50005118
ChEBI
92070
ChEMBL
CHEMBL8809
ZINC
ZINC000025757754
Wikipedia
Raclopride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceEating Disorder1
1CompletedBasic ScienceDepression1
0SuspendedBasic ScienceCocaine Abuse1
Not AvailableCompletedNot AvailableHealthy Volunteers / Parkinson's Disease (PD)1
Not AvailableRecruitingBasic ScienceBMI >27 kg/m2 / BMI >30 kg/m2 / Healthy Volunteers1
Not AvailableWithdrawnNot AvailableSchizophrenia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.126 mg/mLALOGPS
logP3.19ALOGPS
logP2ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)6.26ChemAxon
pKa (Strongest Basic)8.47ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.8 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity88.07 m3·mol-1ChemAxon
Polarizability35.02 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0119000000-60d7b9266bbc9f46e57c

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y, Perez A, Frankle WG, Cooper T, Kleber HD, Fischman MW, Laruelle M: Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology. 2004 Jun;29(6):1190-202. [PubMed:15010698]

Drug created on October 20, 2016 16:41 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates